LynceiSign in
Demo version of Lyncei. People, studies and DOIs are fictional; anyone can sign in to the demo accounts.
You're browsing as a guest. Sign in to post, react, review and follow questions.
20h
Video explainer

Early results from a multicenter trial on SGLT2 inhibitors in heart failure with preserved ejection fraction

The trial reports a reduction in the composite primary outcome. Here's what was measured, who was included, and the limits to keep in mind before changing practice.

Shown because it has a completed review.

[Demo] SGLT2 inhibition in heart failure with preserved ejection fraction: a multicenter trialDemo Journal of Cardiology · 2026doi:10.5555/demo.hfpef.2026
Do SGLT2 inhibitors improve outcomes in heart failure with preserved ejection fraction?
Human expert review completed2 reviews
602
Rigor
Expert-reviewed
Qualified reviewers assessed the methods and statistics. This does not mean the result is settled. Reach (likes, shares) never changes this label.
Sofia MendesNeuroscience · PhD student
1d
Behind the Paper

Why our sleep study surprised us

We expected sleep to help every kind of memory. It didn't. Here's the story of the experiment and what we think is really going on.

Shown because it has a completed review.

[Demo] Sleep-dependent consolidation of declarative memory in adultsDemo Preprints · 2026doi:10.5555/demo.sleep.2026
Does sleep after learning improve long-term memory in adults?
111
Rigor
Source-checked
A reviewer confirmed the post matches its cited source. The underlying study itself has not been assessed. Reach (likes, shares) never changes this label.
23h
Visual

Updated meta-analysis on neoadjuvant immunotherapy in early-stage NSCLC

Event-free survival improves across trials; overall survival data are still maturing.

Shown because it has a completed review.

[Demo] Neoadjuvant immunotherapy in resectable NSCLC: an updated meta-analysisDemo Oncology Reviews · 2026doi:10.5555/demo.nsclc.2026
Does neoadjuvant immunotherapy improve survival in early-stage NSCLC?
Expert review in progress1 of 2
000
Rigor
Source-linked
A source is linked. No one has checked the interpretation yet. Reach (likes, shares) never changes this label.
Dr. Priya ShahEndocrinology
2d
Open Question

Open question: how should we measure long-term adherence to GLP-1 therapy?

Trials run for a few years, but patients may take these drugs for decades. What outcome measures would actually tell us about long-term adherence?

Shown because it's recent.

No source linked
000
Rigor
Unreviewed · no source
No source is linked. Treat this as opinion or an open question. Reach (likes, shares) never changes this label.